Highlights

  • Neurotech advanced NTI164 into a Phase III autism study named Beyond Harmony during 2026.
  • The trial plans to enrol 150 children and evaluates adaptive behaviour alongside other clinical measures.
  • FY26 reporting detailed further work on Rett syndrome, PANS and the NTI164 safety package.
  • The company reported a net loss of $6,538,516 for the year ended 30 June 2026.
  • Clinical outcomes, recruitment and available funding remain central to the development program.

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical company developing NTI164, an oral cannabinoid-based investigational therapy for paediatric neurological disorders. Its 2026 disclosures place autism spectrum disorder (ASD) at the centre of clinical development, alongside research into Rett syndrome and paediatric acute-onset neuropsychiatric syndrome (PANS). The company’s transition to a later-stage ASD study has made clinical trial design, patient recruitment and financial resources important measures of progress.

Beyond Harmony Moves Into Phase III Development

Neurotech International Limited (ASX:NTI) reported that its Beyond Harmony Phase III ASD study received human research ethics approval in February 2026. Its first clinical site was initiated in March 2026 for screening and recruitment. The multicentre, randomised, double-blind, placebo-controlled study is designed to assess NTI164’s efficacy, safety and tolerability in children with moderate-to-severe ASD.

The study plans to enrol 150 patients under an adaptive design. Its primary endpoint is the change in the Vineland-3 Adaptive Behaviour Composite score, a measure of everyday adaptive functioning. Secondary measures include social responsiveness and clinical assessments. In September 2026, Neurotech International Limited (ASX:NTI) announced that the first patient had been dosed in the Phase III study. Trial entry and dosing are development milestones, not evidence that the treatment is effective or approved.

What the Cannabinoid Research Is Testing

NTI164 is described by Neurotech International Limited (ASX:NTI) as a broad-spectrum oral cannabinoid therapy. The company is studying its potential influence on pathways associated with neuroinflammation and neurological function. These proposed mechanisms remain distinct from demonstrating a clinical benefit in a completed registration-enabling trial. The Beyond Harmony study is intended to assess patient outcomes using defined clinical endpoints rather than relying only on laboratory observations.

During 2026, the company also reported research and regulatory activity involving Rett syndrome and PANS. A research collaboration commenced in February 2026 to investigate NTI164’s mechanism in Rett syndrome using human-derived neuronal models. The FY26 annual report also described published PANS data and further non-clinical safety testing. These programs provide additional research context, but findings in one condition cannot establish efficacy in another.

FY26 Financial Position and Development Commitments

For the financial year ended 30 June 2026, Neurotech International Limited (ASX:NTI) reported a consolidated net loss after tax of $6,538,516. The result reflects a business still undertaking clinical development rather than relying on established pharmaceutical product sales. The FY26 directors’ report did not recommend a dividend. Continued clinical recruitment, trial operations, scientific assessment and regulatory preparation involve expenditure before any possible product registration.

The company announced binding commitments for a $4.5 million placement in August 2026. Funding arrangements and the pace of clinical work are relevant because late-stage studies require patient follow-up, data management and regulatory documentation. However, neither trial commencement nor access to new capital establishes the amount of future funding that may be required.

Key Insights

Neurotech International Limited (ASX:NTI) entered FY27 with NTI164 in a Phase III ASD program and parallel research concerning other paediatric neurological conditions. The distinction between earlier clinical observations and confirmatory evidence remains important: trial endpoints, safety findings, recruitment execution and regulatory assessment will determine what can ultimately be established about the investigational treatment.